-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cancer immunosurveillance mainly relies on traditional CD8 T cells to recognize tumor neoantigens (Neoantigen) to kill cancer cells
Cancer immunosurveillance mainly relies on traditional CD8 T cells to recognize tumor neoantigens (Neoantigen) to kill cancer cells
In the past ten years, immunotherapy using targeted antibodies to inhibit PD-1 or PD-L1 to restore the utility function of traditional T cells has achieved certain clinical results and won the 2018 Nobel Prize in Physiology and Medicine
However, while researchers and clinical oncologists hold great promise for immune checkpoint inhibition therapy, its efficacy is often limited by tumor neoantigen mass
At 23:00 on April 20, 2022, the team of Professor Li Ming from Memorial Sloan Kettering Cancer Center (Dr.
In the latest study, the research team first discovered a type of innate killer T cells (Killer Innate -T cells ) that lack PD-1 but highly express the Natural Killer Cell receptor in a mouse breast cancer model (PyMT).
In the latest study, the research team first discovered a type of innate killer T cells (Killer Innate -T cells ) that lack PD-1 but highly express the Natural Killer Cell receptor in a mouse breast cancer model (PyMT).
The research team found that ILTCK does not differentiate from naïve CD8 T cells, but rather from another cell lineage independent of traditional T cells
Li Ming 's team further revealed that interleukin 15 (IL-15) is the key to the activation of ILTCK by cancer cells.
Figure 1: Left: CD8 T cell-depleted tumor immune evasion
Figure 1: Left: CD8 T cell-depleted tumor immune evasion
The discovery of ILTCK provides a new option for tumor immunotherapy
Figure 2: There is a significant positive correlation between the number of T cells similar to mouse ILTCK in the tumor of colorectal cancer patients and the expression of IL-15 in cancer cells
Figure 2: There is a significant positive correlation between the number of mouse ILTCK-like T cells in the tumor of colorectal cancer patients and the expression of IL-15 in cancer cells
Finally, while much of this study focused on mouse models, the team also found ILTCK-like T cells in tissues from human colorectal cancer patients (Figure 2)
Paper link:
https://